pknayak.phe's picture
Dr. Prasanta Kumar Nayak
Assistant Professor
Department of Pharmaceutical Engineering and Technology IIT BHU
Area of Interest: 

  • BPharm (2004): Biju Patnaik University of Technology, Odisha.
  • MPharm (2006): Department of Pharmaceutics, IT (BHU), Varanasi.
  • PhD (2013): Otago School of Medical Sciences, Dunedin, New Zealand.
  • Teaching: ~7 years
  • Academic Research: ~10 years
  • Industrial Research: ~4 years
  • Primarily Prophylactic Pharmacology and Prophylactic Treatment Strategies 
  • Neuropharmacology and Hippocampal Electrophysiology – Stroke, Memory Impairment, Depression, Chronic Diseases
  • Oncology  –  Pathophysiology of Breast Tumors, Brain Tumors, and Colorectal Tumors
  • Undergraduate:
    • BL101-Biology
    • BO202-Human Physiology
    • PH231-General Pharmacology
    • PH432-Neuropharmacotherapeutics
    • UHVII-Universal Human Values-II
    • UHVI-Universal Human Values-I
  • Postgraduate:
    • PH532-Advanced Pharmacology
    • PH534-Clinical Pharmacology​
    • PH535-Advances in Neuropharmacology
    • PH7202-Research Methodology
  • Tej GNVC, Neogi K, Verma SS, Gupta SC, Nayak PK (2019), Caffeine-enhanced anti-tumor immune response through decreased expression of PD1 on infiltrated cytotoxic T lymphocytes. European Journal of Pharmacology, 859, 172538.
  • Shivavedi N., Tej GNVC, Neogi K, Nayak PK (2019), Ascorbic acid therapy: A potential strategy against comorbid depression-like behavior in streptozotocin-nicotinamide-induced diabetic rats. Biomedicine & Pharmacotherapy, 109, 351-359.
  • Tej GNVC, Nayak PK (2018), Mechanistic considerations in chemotherapeutic activity of caffeine. Biomedicine and Pharmacotherapy 105: 312-319.
  • Kumar M and Nayak PK (2017), Therapeutic potential of rosmarinic acid in myocardial infarction and post-myocardial infarction depression: the role of tumor necrosis factor-α. The Pharmstudent 28: 18-26.
  • Kumar M and Nayak PK (2017), Psychological sequelae of myocardial infarction. Biomedicine & Pharmacotherapy 95: 487‒496.
  • Shivavedi N, Kumar M, Tej GN, Nayak PK (2017), Metformin and ascorbic acid combination therapy ameliorates type 2 diabetes mellitus and comorbid depression in rats. Brain Research 1674: 1‒9. doi:
  • Kumar M and Nayak PK (2017), Natural phytochemicals: a promising approach in the management of myocardial infarction. Biomedicine & Pharmacotherapy 92: 1138‒1139.
  • Srivastava P, Kumar M, Nayak PK (2016), Role of patient derived cell lines and xenografts in cancer research. The Pharmstudent 27: 40‒48.
  • Sethi KK, Nayak PK, Sarkar H, Verma SM (2016), A rational approach towards the development of human carbonic anhydrase inhibitors as antiepileptic agent. Med Chem (Los Angeles) 6: 405‒410. doi:10.4172/2161-0444.1000377
  • Nayak PK and Kerr DS (2015), Functional preservation of hippocampal CA1 by low-dose GYKI-52466 preconditioning in a rat model of hypoxic-ischemic brain injury. Brain Research 1613: 100‒109.
  • Nayak PK, Kerr DS (2013), Low-dose GYKI-52466: Prophylactic preconditioning confers long-term neuroprotection and functional recovery following hypoxic‒ischaemic brain injury. Neuroscience 232: 128‒138.
  • Nayak PK, Zhang H and Kerr DS (2013), Determination of 1-(4′-aminophenyl)-4-methyl-7,8-methylene-dioxy-2,3-benzodiazepine by high-performance liquid chromatography–diode array detection in plasma and brain in healthy and hypoxic–ischaemic rats. Neuroscience 232: 139‒150.
  • Mandhane S, Nayak PK, Soni D, Jain S, Ashton J, Rajamannar T (2012), Induction of glucose intolerance by acute administration of rimonabant. Pharmacology 89(5‒6): 339‒347.
  • Bhattamishra SK, Nayak PK, Singh PN, Singh SK (2006), Anti-inflammatory and analgesic activities of Marsilea minuta Linn. Drug Lines 9 (1&2): 42‒45.

PhD Students:
1. Mr Naveen Shivavedi, M.Pharm.
2. Mr Gullanki Naga Venkata Charan Tej, M.Pharm.
3. Mr Kaushik Neogi, M.Pharm.
4. Mr Himanshu Verma, ​M.Pharm.​

M.Pharm./M.Tech. Students:
1. Mr Arijit Ash, B.Pharm.
2. Mr Abinash Baruah, B.Pharm.